Table 1 Baseline characteristics in study patients with and without events
Variables | Total | Events | Non-events | P |
|---|---|---|---|---|
n = 2008 | n = 158 | n = 1850 | ||
Clinical data | ||||
 Age (years) | 55.5 ± 10.9 | 57.5 ± 9.6 | 55.3 ± 11.0 | 0.017 |
 Male sex, n(%) | 1215 (60.6) | 101 (63.9) | 1114 (60.2) | 0.360 |
 BMI (kg/m2) | 25.7 ± 3.4 | 26.0 ± 3.5 | 25.6 ± 3.4 | 0.185 |
 CAD, n(%) | 1179 (58.7) | 121 (76.6) | 1058 (57.2) | < 0.0001 |
 DM, n(%) | 471 (23.5) | 54 (34.2) | 417 (22.5) | 0.001 |
 Hypertension, n(%) | 1229 (61.2) | 107 (67.7) | 1122 (60.6) | 0.080 |
 Family history of CAD, n(%) | 440 (21.9) | 22 (13.9) | 418 (22.6) | 0.011 |
 Smoking, n(%) | 683 (34.0) | 56 (35.4) | 627 (33.9) | 0.693 |
 Drinking, n(%) | 417 (20.8) | 35 (22.2) | 382 (20.6) | 0.655 |
 SBP (mmHg) | 127.6 ± 18.5 | 130 ± 16.9 | 127.4 ± 18.7 | 0.099 |
 DBP (mmHg) | 79.5 ± 11.2 | 79.8 ± 11.8 | 79.5 ± 11.1 | 0.710 |
Laboratory parameters | ||||
 Platelet (109/L) | 216.0 ± 53.6 | 208.7 ± 51.1 | 216.6 ± 53.8 | 0.075 |
 ALT (IU/L) | 20 (14,28) | 21 (14,29) | 20 (14,28) | 0.472 |
 AST (IU/L) | 18 (15,22) | 18 (14.75,22) | 18 (15,22) | 0.806 |
 GGT (IU/L) | 25 (18,39) | 30 (21,44.25) | 25 (18,39) | < 0.0001 |
 ALB (g/L) | 42.5 ± 4.3 | 41.9 ± 3.8 | 42.6 ± 4.3 | 0.060 |
 TC (mmol/L) | 4.80 ± 1.01 | 5.00 ± 0.94 | 4.80 ± 1.01 | 0.095 |
 TG (mmol/L) | 1.60 (1.15,2.31) | 1.60 (1.24,2.36) | 1.60 (1.14,2.30) | 0.541 |
 HDL-C (mmol/L) | 1.11 ± 0.39 | 1.13 ± 0.35 | 1.11 ± 0.39 | 0.539 |
 LDL-C (mmol/L) | 3.13 ± 0.91 | 3.24 ± 0.81 | 3.12 ± 0.92 | 0.128 |
 Glucose (mmol/L) | 5.66 ± 1.96 | 5.91 ± 2.61 | 5.64 ± 1.90 | 0.094 |
 HbA1C (%) | 6.05 ± 1.88 | 6.3 ± 1.11 | 6.03 ± 1.93 | 0.081 |
 PCSK9 (ng/mL) | 228.56 (190.57,272.29) | 245.23 (204.53,292.15) | 227.58 (189.93,270.97) | 0.002 |
 NFS | −1.09(−1.98,-0.27) | −0.77(−1.53,0.05) | −1.12(−2.00,-0.29) | < 0.0001 |
Medication | ||||
 Antiplatelet drugs, n(%) | 595 (29.6) | 65 (41.4) | 530 (28.6) | 0.001 |
 Antihypertensive drugs, n(%) | 694 (34.6) | 67 (42.4) | 627 (33.9) | 0.031 |